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a b s t r a c t
Objective: For extended-release drugs with multi-compartment kinetics, such as topiramate, effective
half-life (t1/2eff ) may be a more clinically relevant parameter than elimination half-life (t1/2z ). Using topiramate as a real-life example, the objective was to compare these half-life values for immediate- and
extended-release topiramate (TPM-IR and USL255, respectively) to understand how drug pharmacokinetics may impact drug dosing recommendations.
Methods: The t1/2z and t1/2eff for USL255 and TPM-IR were compared using data from a phase I study (N = 36)
of 200 mg USL255 administered once daily (QD) or TPM-IR twice daily (BID); effect of sampling duration
on t1/2z was investigated. To further explore the relationship between half-life and dosing, steady-state
PK was simulated for USL255 and TPM-IR.
Results: As previously reported, mean t1/2z was similar between USL255 (80.2 h) and TPM-IR (82.8 h); TPMIR t1/2z was ∼4 times longer than reported in the Topamax label (21 h). In contrast, USL255 displayed a
1.5 fold longer t1/2eff (55.7 vs 37.1 h for TPM-IR). When t1/2z was calculated from 48 to 336 h, values
ranged from 28.8 to 82.8 h. Simulated steady-state PK proﬁles of USL255 QD exhibited reduced plasma
ﬂuctuations during a dosing interval vs TPM-IR QD or BID.
Signiﬁcance: As expected for the same moiety, t1/2z of USL255 and TPM-IR were similar; however, the
longer t1/2eff for USL255 better approximates differences in recommend dosing (QD USL255 vs BID TPMIR). Further, sampling duration impacted t1/2z , diminishing its predictive value for determining dose
regimens; sampling-time differences may also explain t1/2z discrepancy between TPM-IR here versus
Topamax label. As expected, steady-state simulations conﬁrm that although TPM-IR has a long t1/2z ,
taking TPM-IR QD would lead to large plasma ﬂuctuations. These data demonstrate that t1/2z may be
less clinically meaningful than t1/2eff, and using t1/2z for some drugs may lead to erroneous conclusions
regarding dosing regimens.
© 2016 The Author(s). Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Appropriate interpretation of pharmacokinetic (PK) data is crucial when optimizing antiepileptic drug (AED) therapy. It is equally
important that one not misapply either pharmacokinetic data, or
the underlying mathematical principles of PK when constructing
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an individualized AED dosing regimen. One of the oldest, and most
fundamental concepts in pharmacotherapy is that of drug half-life
(t1/2 ). The simple deﬁnition of t1/2 is the time interval over which
the amount of drug in the body is decreased by one-half. A common
misconception is that t1/2 is synonymous with clearance, which is
not completely accurate. In fact, t1/2 is a hybrid parameter that takes
into account drug clearance as well as its volume of distribution (ie,
drug distribution between plasma and the rest of the body after dosing). Therefore, a better way of viewing t1/2 is that it is a predictor
of drug accumulation and ﬂuctuation in plasma concentration.
Clinicians may use t1/2 to guide them in individualizing dosage
regimens for patients. Understanding t1/2 is particularly important
when determining dosing intervals for chronically-administered
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drugs, as dosing adjustments may impact a drug’s systemic exposure (ie, area under the concentration-time curve [AUC]) and
plasma ﬂuctuations. For example, if a drug is administered at a
steady-state frequency equal to its t1/2 , then AUC during that dosing interval will be twice that seen following a single dose (Sahin
and Benet, 2008); this is due to drug accumulation over time as a
repeated dose is given prior to disappearance of the previous dose.
Giving a drug more frequently than its t1/2 will result in more drug
accumulation, with the opposite occurring if that drug is given less
frequently than the t1/2 (Grover and Benet, 2011). With regards to
plasma ﬂuctuations, dosing a drug more frequently than its t1/2 will
result in a ﬂatter plasma concentration-time curve (ie, less ﬂuctuation) than if that same daily dose were being given less frequently
(Grover and Benet, 2011).
Though half-life is a key pharmacokinetic parameter in determining drug dosing, it is important to note that drugs may exhibit
multiple half-lives, depending on how they distribute into tissues
throughout the body following dosing. As such, different methods
can be used to calculate a drug’s half-life. In practice, clinicians will
often use terminal elimination half-life (t1/2z ) to guide drug dosing,
as this is the most widely published half-life value and the one
typically reported in prescribing information. The t1/2z for a drug
is deﬁned as drug elimination during the terminal phase, which is
the ﬁnal elimination phase following drug absorption and redistribution into body tissues.
For drugs with simple linear pharmacokinetics, t1/2z may be
an accurate measure of a drug’s half-life. However, for drugs with
slower absorption, multi-compartment distribution into different
tissues, and multi-exponential disposition, t1/2z may be a poor predictor of drug accumulation and ﬂuctuation. This is illustrated in
Fig. 1A, which depicts a hypothetical plasma concentration-time
proﬁle for a drug that distributes into multiple compartments. As
t1/2z describes drug elimination during the terminal phase (after
drug absorption and distribution has entirely completed), t1/2z may
only describe a very small fraction of the plasma concentrationtime curve (Bialer and Soares-da-Silva, 2012). Therefore, t1/2z will
probably not describe concentration decline during a dosage interval for drugs with more complex absorption and distribution
characteristics, such as extended-release formulations that are
speciﬁcally designed to have a slower absorption proﬁle. Another
limitation of t1/2z is that the value can be impacted by PK assay
methods, including sampling duration, assay sensitivity, and sampling frequency. For example, sampling duration (ie, the duration of
time over which plasma samples are taken) can change the phase
when half-life is measured, thereby impacting the resulting t1/2z
value (Fig. 1A).
Given that most antiepileptic drugs (AEDs) will likely display
multi-compartment kinetics, which half-life should the clinician
use? If our clinical objective is to dose a drug that can be given as
infrequently as possible, with minimal plasma concentration ﬂuctuation and consistent exposure during the dosage interval, then
use of the commonly accepted and published value of t1/2z may
be incorrect for many AEDs. Indeed, using this value may result in
suboptimal dosing predictions (Sahin and Benet, 2008). Therefore,
a more clinically relevant half-life measure may be effective halflife (t1/2eff ), which describes the rate of drug loss across the entire
dosing interval.
Unlike t1/2z , which is calculated using the slope of the last drug
elimination phase following single-dose administration (Fig. 1A;
Eq. (1)), t1/2eff takes into consideration the entire concentrationtime proﬁle of a drug. The t1/2eff is calculated based on both the
drug-dosing interval and drug accumulation over time following
multiple-dose administration (Fig. 1B; Eq. (2)) (Boxenbaum and
Battle, 1995). As a result, t1/2eff is expected to be less affected by
sampling duration compared with t1/2z , and its calculation only
requires sampling over the dosing interval following a single dose
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and at steady state. Thus, using t1/2eff to guide dosing may be particularly beneﬁcial when long-term maintenance of therapeutic levels
is required.
Overall, the use of t1/2eff in lieu of t1/2z may be particularly
beneﬁcial for extended-release AEDs with multi-compartment
kinetics. Topiramate (TPM) is one such agent; Gidal and Lensmeyer
demonstrated that TPM partitions in a saturable manner into erythrocytes (Gidal and Lensmeyer, 1999). The release of TPM from this
high-afﬁnity red blood cell compartment—presumably to carbonic
anhydrase—likely contributes to reduced apparent oral clearance
and volume of distribution at low concentrations (Shank et al.,
2005). These properties of TPM make it an ideal candidate to compare the clinical utility of these two half-life measures.
Using TPM as a real-life example, the objective of this
manuscript is to understand how the pharmacokinetics of
immediate-release (IR) and extended-release (XR) formulations
may impact drug dosing recommendations. First, the t1/2eff and
t1/2z of IR and XR TPM will be compared to demonstrate how both
formulation differences and methodology impact half-life values.
Additionally, steady-state proﬁles will be simulated to understand
how varying drug dosing (ie, once- vs twice-daily dosing) impacts
the pharmacokinetics of IR versus XR formulations. Together, the
use of TPM—an AED with IR and XR formulations—will demonstrate
which half-life measure may be more clinically-useful in determining appropriate dosing intervals.
2. Methods
2.1. Comparison of elimination and effective half-Lives for
USL255 and TPM-IR
The two TPM formulations evaluated were once-daily (QD)
USL255, Qudexy® XR (topiramate) extended-release capsules
(Upsher-Smith Laboratories, Inc. (Qudexy® , 2015)) and twice-daily
(BID) IR topiramate (TPM-IR; Topamax® ; Janssen Pharmaceuticals
(Topamax® , 2009)). Half-life values were assessed from a phase
I, randomized (N = 36), open-label, crossover study of single-dose
USL255 200 mg and 2 doses of TPM-IR 100 mg dosed every 12 h
(Lambrecht et al., 2011). The t1/2z and t1/2eff for USL255 and TPMIR were previously calculated (Eqs. (1) and (2)) (Lambrecht et al.,
2011). In brief, t1/2z is calculated by dividing the natural log of 2 by
the slope of the last phase (z), which is dependent on the blood
sampling duration used for PK analyses (Fig. 1, Eq. (1)).
t1/2z = ln2/z

(1)

In contrast, t1/2eff is calculated based on dosing interval
() and drug accumulation over time following multiple-dose
administration (ie, drug accumulation index [Rac = steady-state
AUC0- /single-dose AUC0- ]; Eq. (2)).
t1/2eff =  ∗ ln2/ln[Rac/(Rac − 1)]

(2)

To determine how the plasma sampling duration for PK calculations can impact half-life, t1/2z was calculated using data from the
48, 72, 168, 264, and 336 h PK sampling times of the phase I study
for both USL255 and TPM-IR. Detailed information regarding participants and topiramate analyses are described in Lambrecht et al.
(Lambrecht et al., 2011).
2.2. Simulated steady-state pharmacokinetic proﬁles for USL255
and TPM-IR
Simulations were used to predict steady-state plasma
concentration-time proﬁles of USL255 administered QD and
TPM-IR 200 mg administered QD or BID; approved dosing is QD
for USL255 and BID for TPM-IR (Qudexy® , 2015; Topamax® , 2009).
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Fig. 1. Hypothetical Proﬁles Used to Calculate Elimination and Effective Half-Lives.
(A) Illustrated here is a hypothetical plasma concentration-time proﬁle following a single dose of a 3-compartment drug. In the ␣ phase, a rapid decrease in plasma levels is
due to drug distribution from circulation (central compartment) into body tissues (peripheral compartments); this phase ends with pseudo-equilibrium of drug concentration
between the central and peripheral compartments. The ␤ phase describes a slower decrease in plasma drug levels due to drug metabolism and excretion from the body. The
␥ phase can occur later when tissue-bound drug is released into circulation then eliminated from the body; the ␥ phase may be associated with very small and insigniﬁcant
amount of drug distribution. The slope of the last phase (z) is used to calculate t1/2z . In this example, the ␥ phase would be used, as the sampling duration extended to 24 h.
If the sampling duration was only 12 h, the ␤ phase would be used to calculate t1/2z . Together, this ﬁgure illustrates how sampling duration may impact elimination half-life,
and result in t1/2z estimates not being predictive of drug accumulation.
(B) Depicted is a hypothetical drug plasma accumulation following multiple doses of a drug dosed every 12 h. This graph describes the variables used to calculate t1/2eff : drug
dosing interval () and drug accumulation index (Rac; steady-state AUC0- /single-dose AUC0- ). AUC (area under the plasma concentration-time curve), is represented by the
shaded boxes. In this hypothetical example,  = 12 h and Rac = 2. Figure modiﬁed from Boxenbaum H and Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol
1995; 35:763–766 (Boxenbaum and Battle, 1995).

For USL255, a 2-compartment population PK model with sigmoid
absorption and ﬁrst-order elimination was developed from data
obtained from 158 healthy male and female participants enrolled
in four phase I studies (Bialer et al., 2013; Clark et al., 2014, 2016;
Lambrecht et al., 2011). Covariate effects included allometric
effects of weight on apparent oral clearance of topiramate (CL/F)
and on apparent volume of distribution within the central compartment, and the effects of creatinine clearance on CL/F. TPM-IR
was simulated using a modiﬁed 2-compartment linear population
PK model with ﬁrst order absorption as previously described
(Girgis et al., 2010; Marathe, 2010). Covariate effects of weight on
CL/F in the TPM-IR model were included.
Using the models described above, steady-state concentrationtime proﬁles of USL255 QD and TPM-IR 200 mg/day QD or BID

were simulated in a virtual population of 250 healthy individuals using NOMMEM® (ICON, Ellicott City, MD), and validated
against observed data (Bialer et al., 2013). The virtual participant
population for each formulation was generated through random
re-sampling of participant characteristics in the USL255 model
development dataset, keeping weight and creatinine clearance values together in the same individual. Steady-state simulations were
used to compare the minimum observed drug plasma concentration (Cmin ), maximum observed drug plasma concentration (Cmax ),
and ﬂuctuation index ([Cmax − Cmin ]/Cavg *100, where Cavg is the
average drug plasma concentration) of USL255 and TPM-IR.
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3. Results
3.1. Comparison of terminal and effective half-lives for USL255
and TPM-IR
The half-lives of USL255 and TPM-IR were evaluated in a prior
phase I study of 36 healthy volunteers following a single dose
of 200 mg USL255 QD and 200 mg TPM-IR BID (Lambrecht et al.,
2011). As expected, the mean t1/2z was similar for USL255 and TPMIR (80.2 h vs 82.8 h (Lambrecht et al., 2011)), despite differences
in drug formulations and dosing recommendations. In contrast,
the t1/2eff for USL255 was 1.5 fold longer than TPM-IR (55.7 h vs
37.1 h (Lambrecht et al., 2011)). This marked difference in t1/2eff
between an immediate- and extended-release formulation is not
unexpected, as effective half-life takes into account drug accumulation over the dose interval. Further, t1/2eff values were shorter
than t1/2z for both USL255 and TPM-IR (55.7 vs 80.2 h for USL255
and 37.1 vs 82.8 h for TPM-IR, respectively).
3.2. Effect of sampling duration on terminal half-life values
For TPM-IR, mean terminal half-life of 82.8 h (Lambrecht et al.,
2011), is almost 4-times longer than the 21 h value reported in the
TPM-IR prescribing information (Topamax® , 2009). Because terminal half-life is dependent upon assay methodology, we investigated
sampling duration as a factor for this large difference. Thus, t1/2z
was calculated for USL255 and TPM-IR using different sampling
durations from the dataset (Fig. 2). As sampling duration increased
from 48 to 336 h, t1/2z increased for both USL255 and TPM-IR, independent of the formulation, with large ranges in value (USL255,
35.6–80.2 h; TPM-IR, 28.8–82.8 h). Interestingly, the 28.8 h half-life
observed for TPM-IR at 48 h (Fig. 2) is in alignment with the 21 h
half-life reported in the prescribing information, which was based
upon a 32 h sampling time (Topamax® , 2009).
3.3. Simulated steady-state pharmacokinetic proﬁles for USL255
and TPM-IR
The simulated steady-state plasma concentration-time proﬁles
for a typical individual receiving 200 mg/day USL255 or TPM-IR
administered as a single 200 mg dose (QD) or two 100 mg doses
(BID) are shown in Fig. 3. Validity of this simulation was supported
by the similarity between observed steady-state phase I data of
200 mg/day USL255 QD and TPM-IR BID administered for 14 days
(Bialer et al., 2013) and the simulated steady-state proﬁles. Based
upon these simulations it is evident that although TPM-IR has a
long t1/2z (>80 h), QD dosing based upon t1/2z would lead to large
plasma ﬂuctuations.
Evaluation of the recommended dosing regimen for USL255
and TPM-IR showed that mean predicted ﬂuctuation index for
USL255 QD was 18% lower than TPM-IR BID (0.23 vs 0.28), with
a 47% decrease in the maximum ﬂuctuation index (0.67 USL255
QD vs 1.27 TPM-IR BID). This difference is not unexpected, due
to the greater predicted variability in Cmin and Cmax concentrations with TPM-IR BID compared with USL255 QD (Fig. 3; Table 1).
Higher minimum plasma concentration for USL255 may have been
a primary reason for this difference in ﬂuctuation index, as mean
predicted Cmin for USL255 QD was 7.4% higher compared with TPMIR BID, with little difference in mean predicted Cmax (1.5% higher
for USL255 vs TPM-IR; Table 1).
Though the comparison above included two drugs with different
formulations (XR vs IR) and different dosing schedules (BID vs QD),
similar trends are expected when keeping either formulation or
dosing schedule consistent. For example, dosing XR and IR formulations on a similar schedule would be predicted to result in large
ﬂuctuation index differences; as expected, USL255 QD had a 65%
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Table 1
Predicted steady-state PK parameters of USL255 and TPM-IR administered once or
twice daily.
USL255

TPM-IR

QD

BID

QD

Cmin , g/mL
Mean (SD)
Median
Range

6.05 (1.53)
5.96
3.28–11.8

5.63 (1.74)
5.62
1.65–11.2

4.73 (1.99)
4.51
1.07–12.9

Cmax , g/mL
Mean (SD)
Median
Range

7.60 (1.72)
7.44
4.20–13.8

7.48 (2.39)
7.04
2.14–16.8

9.04 (3.59)
8.39
1.68–25.7

Fluctuation Index
Mean (SD)
Median
Range

0.23 (0.09)
0.21
0.06–0.67

0.28 (0.21)
0.21
0.07–1.27

0.66 (0.46)
0.52
0.08–2.42

Abbreviations: BID, twice daily; Cmax , maximum plasma concentration; Cmin , minimum plasma concentration; max, maximum; min, minimum; PK, pharmacokinetic;
QD, once daily; SD, standard deviation; TPM-IR, immediate-release topiramate;
USL255, extended-release topiramate.

lower mean predicted ﬂuctuation index versus TPM-IR QD (0.23 vs
0.66; Fig. 3; Table 1). Similarly, dosing the same formulation more
frequently would be predicted to reduce plasma ﬂuctuations; as
expected, BID administration of TPM-IR resulted in a 47% decrease
in the mean predicted ﬂuctuation index compared with QD dosing
(0.28 vs 0.66; Fig. 3; Table 1). The reduced plasma ﬂuctuation with
BID dosing was due to a 19% higher mean predicted Cmin and 17%
lower mean predicted Cmax versus QD dosing.
4. Discussion
Selection of an appropriate dosing interval is an important clinical decision. While many clinicians and clinical scientists have
been taught that elimination half-life (t1/2z ) is the most useful
parameter to guide dosing decisions (Sahin and Benet, 2008),
this half-life value may not optimally characterize the steadystate concentration-time proﬁle for many drugs (Dutta and Reed,
2006). A more appropriate parameter to predict drug accumulation
and describe elimination at steady state may be effective half-life
(t1/2eff ), which considers the entire plasma concentration-time proﬁle of the drug and may better reﬂect total clearance (Boxenbaum
and Battle, 1995). This may be particularly the case in situations
where clinicians opt to use newer extended-release formulations
of existing agents.
A goal of this manuscript was to use TPM as a real-life example
to understand how drug PK—including half-life—may impact drug
dosing recommendations. Results from these analyses suggest that
half-life measures can be inﬂuenced by drug formulation (ie, XR and
IR) and methodology (ie, PK sampling time). This was conﬁrmed
with observed data from TPM demonstrating that t1/2z is insensitive
to formulation differences and varies depending on drug sampling
time whereas t1/2eff may better approximate differences between
XR and IR TPM.
When determining the impact of drug formulation on PK, one
might think that an extended- and immediate-release formulation
of the same active moiety would have different half-life values.
However, the t1/2z for USL255 and TPM-IR are nearly identical
(80.2 vs 82.8 h, respectively), and no large difference in t1/2z was
observed between these 2 formulations when sampling time was
kept consistent (Fig. 2). This similar t1/2z for USL255 and TPM-IR
may lead to the incorrect assumption that changes in plasma concentration over 24 h are similar between XR and IR formulations
or that IR drugs may be dosed less frequently. In contrast, the 1.5fold higher t1/2eff for USL255 versus TPM-IR (55.7 vs 37.1 h) better
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Fig. 2. Impact of Pharmacokinetic Sampling Duration on Elimination Half-Life of 200 mg USL255 and TPM-IR.
t1/2z calculated at each sampling duration (black arrows) for 200 mg/day USL255 and TPM-IR is presented under the concentration-time proﬁle for both topiramate formulations. Linear scale is shown in panel A and log scale shown on panel B. Samples for TPM-IR were taken following the 2nd BID dose (eg, 48 h equals 36 h post 2nd dose,
72 h equals 60 h post 2nd dose, etc). Figure was modiﬁed from Lambrecht LJ et al. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release
formulation of topiramate. Epilepsia 2011;52(10):1877–83 (Lambrecht et al., 2011).
Abbreviations: BID, twice daily; QD, once daily; t1/2z ; elimination half-life; TPM-IR, immediate-release topiramate; USL255, extended-release topiramate.

approximates the difference in recommend dosing between the
2 formulations (QD vs BID, respectively). Similar results for other
AEDs also have demonstrated that t1/2eff may be more clinically
meaningful than t1/2z . Dutta and Reed demonstrated that although
valproic acid has a t1/2z of 12–16 h, the t1/2eff of divalproex-ER over a
dosage interval was in fact 40 h (due to its prolonged drug release),
supporting its once-per-day administration (Dutta and Reed, 2006).
Likewise, for the AED eslicarbazepine acetate, t1/2eff corresponds
well with its once-daily dose interval. Based upon its absorption
rate as well as metabolite formation rate and dosage interval,
eslicarbazepine accumulation ratio translated into an t1/2eff for eslicarbazepine of 20–24 h, or about twice as long as its t1/2z (Bialer and
Soares-da-Silva, 2012).
In addition to being unaffected by drug formulation differences,
t1/2z can also be impacted by clinical methodology. As described
above, the 82.8-h t1/2z reported for TPM-IR (Lambrecht et al., 2011)
is almost 4-times longer than the 21-h value reported in the TPM-IR
label (Topamax® , 2009). Though the half-life value from Lambrecht
et al. may seem contradictory to the Topamax prescribing information, this discrepancy in t1/2z is likely due to methodology and
not due to an actual difference in half-life. For example, the sensitivity of the PK assay was increased for Lambrecht and colleagues

versus the Topamax prescribing information (10 ng/mL lower limit
of quantiﬁcation [LLOQ] vs 500 ng/mL LLOQ, respectively); further, Lambrecht et al. had a longer sampling duration (336 vs 32 h,
respectively). To demonstrate how sampling time can impact t1/2z ,
TPM-IR and USL255 were evaluated at various time points. As sampling duration increased from 48 to 336 h, the t1/2z also increased
from approximately 30 to 80 h (Fig. 2). It is important to note that
this large impact of sampling time on t1/2z is not a universal feature for all drugs; for TPM, its multi-compartment PK may make it
more sensitive to sampling time compared with a drug that does
not distribute into multiple tissue compartments (see Fig. 1A for a
hypothetical example on how sampling time may impact t1/2z ).
Taken together, these data suggest that t1/2z may not accurately
represent a clinically meaningful elimination or accumulation estimate of an extended-release drug, and use of t1/2z may result in an
inaccurate prediction of the appropriate dosing interval.
A limitation of these analyses is the evaluation of PK in healthy
individuals and not patients with epilepsy; as such, speciﬁc factors
that may inﬂuence PK may not be represented (eg, concomitant
use of cytochrome inducers or inhibitors). FDA guidance often recommends PK analyses in healthy individuals, which may limit
confounding factors, and data from healthy individuals are often
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Fig. 3. Mean Predicted Steady-State Plasma Topiramate Concentrations of USL255 and TPM-IR Administered QD or BID.
Simulated steady state based on mean predicted plasma concentration-time proﬁles for 200 mg/day USL255 and TPM-IR once- or twice-daily are shown.
Abbreviations: BID, twice daily; QD, once daily; TPM-IR, immediate-release topiramate; USL255, extended-release topiramate.

used in modeling analyses to evaluate drug PK. Further, results
from these analyses were not intended to serve as direct clinical
outcome data. A detailed comparison of t1/2z and t1/2eff —using TPM
as a real-life example—was used to illustrate how formulation and
methodological differences may impact half-life values, which has
implications in patient care.
For example, in cases where clinicians choose to implement
a dosing schedule that differs from the approved dosing recommendations of a given drug, understanding half-life is particularly
important. For patients who are already on concomitant BID drugs,
some clinicians may recommend taking the same total daily dose
of a QD drug (with a long half-life) twice daily to potentially reduce
plasma ﬂuctuations and simplify the overall drug regimen. Conversely, a clinician may assume that a BID drug with an ∼24-h
half-life could be administered QD. For example, the 21-h reported
t1/2z for TPM-IR (Topamax® , 2009) may be interpreted to mean QD
dosing is acceptable. However, QD dosing may not be optimal based
on the predicted steady-state proﬁle of TPM-IR, which showed
increased plasma ﬂuctuations compared with TPM-IR BID (Fig. 3).
These data, using TPM as an example, underscore the importance
of understanding the clinical relevance of half-lives reported in a
drug’s prescribing information. Additionally, while half-life may be
one parameter used to guide dosing, assessing the entire steadystate proﬁle may provide additional information when optimizing
a dosing regimen.
It is important to note that neither t1/2z nor t1/2eff for USL255 and
TPM-IR are identical to recommended dosing intervals for these
drugs. This is because half-life alone may not provide all of the
information necessary to construct an appropriate dosing regimen,
as additional pharmacodynamic effects of a drug (eg, therapeutic index and receptor binding afﬁnity/duration of binding) may
inﬂuence drug distribution. Additionally, drugs can be dosed more
frequently than recommended by half-life values, as dosing may be
optimized to decrease ﬂuctuations in plasma concentrations.
USL255 was developed to provide relatively consistent plasma
drug concentrations across a 24-h dosing interval with reduced
ﬂuctuations compared with TPM-IR (Bialer et al., 2013). This is supported by the steady-state simulations shown here, which revealed

that USL255 QD had a smaller ﬂuctuation index and higher Cmin
than TPM-IR QD or BID (Fig. 3). The mean predicted ﬂuctuation
index for USL255 QD was reduced by 18% compared with TPMIR BID, which is slightly lower than the observed 26% decrease
in ﬂuctuation index with USL255 QD versus TPM-IR BID following steady-state dosing in healthy volunteers (Bialer et al., 2013).
This difference may be due in part to limitations in our methodology; while data from the Bialer et al. study were used to estimate
t1/2eff for USL255 and TPM-IR, the models used here were from the
literature. Therefore, the proﬁles in this analysis were developed
using 2 different data sets (ie, not the same participants).
The predicted steady-state proﬁles for USL255 and TPM-IR provide a better understanding of XR versus IR topiramate PK, which
may be considered when determining drug choice and dosing. In
general, XR AEDs tend to have reduced plasma ﬂuctuations and
ﬂatter plasma concentration-time curves than their IR counterparts (Pellock et al., 2004), a pattern that also was observed for
USL255 and TPM-IR. A ﬂatter steady-state curve for XR AEDs may be
favorable for patients who require dosing adjustments, particularly
increased doses, to maintain seizure control without precipitating
any adverse events associated with peak concentrations (Pellock
et al., 2004).

5. Conclusions
The commonly referenced elimination half-life (t1/2z ) may not
be adequate or appropriate in many circumstances. Effective halflife, or t1/2eff , may indeed be more clinically relevant as it takes into
consideration the entire concentration-time proﬁle of a drug. This
is particularly true when comparing dosing requirements between
immediate and extended-release product formulations. However,
half-life is not the only parameter used to determine dosing regimens. The importance of recommended dosing from prescribing
information is illustrated by the simulations of TPM-IR; while
once-daily dosing may seem appropriate with its long reported
half-life, doing so may result in large plasma ﬂuctuations. Together
with the comparison of t1/2eff and t1/2z , these data underscore the
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importance of understanding half-life measures, and may improve
clinicians’ understanding of dosing regimens.
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